About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. Segments The company operates through four segments, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Pharmaceuticals Pharmaceuticals development, production and marketing of prescription products, especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. This segment also included the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents. Its portfolio includes a range of key products that are among the major pharmaceuticals for their indications. The prescription products from Pharmaceuticals are primarily distributed through wholesalers, pharmacies and hospitals. The company’s main products and brands include Xarelto, Adalat, Aspirin Cardio, Adempas, Nexavar, Xofigo, Stivarga, Aliqopa, Vitrakvi, Eylea, Kogenate/Kovaltry/Jivi, Mirena product family, Yaz/Yasmin/Yasminelle, Visanne, Avalox/Avelox, Cipro, Ciprobay, Gadovist, Ultravist, Medrad Spectris Solaris, Medrad Stellant, and Betaferon/Betaseron. Consumer Health Consumer Health development, production and marketing of mainly nonprescription (over-the-counter) medicines, medical products, cosmetics and other self-care solutions in the categories of dermatology, nutritional supplements, pain, digestive health, allergy, cough and cold, foot care and sun protection categories. The products are sold by pharmacies, supermarket and drugstore chains, online retailers and other large retailers. The company's main products and brands include Bepanthen, Canesten, One A Day, Elevit, Berocca, Supradyn, Redoxon, Aspirin, Aleve, MiraLAX, Rennie, Iberogast, Clariti, Aspirin, Alka-Seltzer, Afrin, Dr. Scholl’s, and Copperton. Crop Science Crop Science offers a portfolio of seeds, plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The company markets these products primarily through wholesalers and retailers or directly to farmers. In addition, it markets pest and weed control products and services to professional users outside the agriculture industry. Most of its cropprotection products are manufactured at the segment’s own production sites. The company’s main products and brands include Roundup, Adengo, Alion, Corvus, Atlantis, Harness, Warrant, Dekalb, SmartStax RIB Complete, VT Double PRO, VT Triple PRO, Asgrow, Intacta RR2PRO Roundup Ready 2 Xtend, Roundup Ready 2 Yield, Flint, Fox, Luna, Nativo, Prosaro, Serenade, Xpro, BioAct, Confidor, Movento, Sivanto, Ficam, Maxforce, Esplanade, K-Othrine, Seminis, DeRuiters, Climate FieldView, Gaucho, Bollgard II, Bollgard II XtendFlex, and Deltapine. Animal Health Animal Health Development, production and marketing of prescription and nonprescription veterinary products. The company develops products and solutions for the prevention and treatment of diseases in companion and farm animals. The company markets its animal health products globally through veterinarians and other distribution channels, such as pharmacies or retail stores. The company’s main products and brands include Advantage product family, Seresto, Drontal product family, Baytril Baytril, and Cydectin. The company offers tailored solutions to reflect the specific needs of its customers’ farms, crops and soil. Strategy The company’s strategy is to seek to contribute to medical progress through its focus on researching, developing and marketing innovative medicines, primarily in the therapeutic areas of cardiology, oncology, women’s health, hematology and ophthalmology. The company’s strategy moving forward would accelerate its core categories, geographies and the transfer of prescription medicines and active ingredients to nonprescription status. The company’s strategy is to work with innovative partners and utilize new technologies, including advanced seed scripting tools, that combine multiple data sets as it look to support farmers with seed selection, placement and seeding density, helping them to better reach their farming potential. The company’s strategy is based on three key elements: innovation, sustainability and digital transformation. Its strategy is to work with innovative partners and utilize new technologies, including advanced seed scripting tools, that combine multiple data sets as it looks to support farmers with seed selection, placement and seeding density, helping them to better reach their farming potential. The company focuses on maximizing the continued growth of the innovative Seresto collar, opening new distribution channels and leveraging the brand equity of its advantage product family. In the farm animals business, the company is commercializing and developing antiparasitics and antiinfectives. The company is continuing to strengthen its customer engagement while also driving crossspecies initiatives, such as the antibiotic stewardship program promoting the responsible use of antibiotics. Divestments In 2018 In connection with the acquisition of Monsanto Company, the company signed an agreement with BASF SE on October 13, 2017, concerning the sale of selected Crop Science businesses. All of the transactions closed on August 1, 2018, apart from the divestment of the vegetable seed business, which closed on August 16, 2018. In 2018, the U.S. activities of the prescription dermatology business within the Consumer Health segment were transferred to the acquirer LEO Pharma A/S, Ballerup, Denmark. In 2018, the Pharmaceuticals segment sold its MK Generics business in Central America and the Caribbean to Tecnoquímicas S.A., Cali, Colombia. The divested business includes the Bonima production plant in El Salvador. Collaborations The company has collaborations with BASF SE; Brazilian Agricultural Research Corporation –Embrapa; 2Blades Foundation; Citrus Research Development Foundation, Inc.; Elemental Enzymes Ag and Turf, LLC; Energin .R Technologies 2009 Ltd.; Evogene Ltd.; Forschungszentrum Jülich GmbH; Grains Research and Development Corporation; Innovative Vector Control Consortium; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas in Greece (IMBB-FORTH); KWS SAAT SE; Nimbus Discovery, Inc.; Nomad Bioscience GmbH; Novozymes A/S; Pairwise Plants; Pivot Bio; Second Genome, Inc.; and Targenomix GmbH. In 2018, global license agreements were concluded with Mitsui Chemicals Agro, Inc. and NeuroCycle Therapeutics to strengthen the portfolio. In January 2019, the company and Kyoto University agreed on a strategic research alliance to jointly identify new drug targets for the treatment of pulmonary diseases, such as idiopathic pulmonary fibrosis. Significant Events In October 2019, Bayer Animal Health GmbH and VLPbio – The Vaccines Company S.L. signed a worldwide collaboration agreement to discover and develop a new generation of immunotherapeutic solutions that address the demand for treatment options in the field of veterinary medicine. In December 2020, the company and Atara Biotherapeutics, Inc. announced a license, research, development, and manufacturing collaboration agreement for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. History Bayer Aktiengesellschaft was founded in 1863.

Country
Industry:
Chemicals and allied products
Founded:
1863
IPO Date:
01/01/1992
ISIN Number:
I_DE000BAY0017
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, North Rhine-Westphalia, 51368, Germany
Phone Number
49 214 30 1

Key Executives

CEO:
Anderson, William
CFO
Nickl, Wolfgang
COO:
Data Unavailable